Commentary|Podcasts|July 15, 2025

COBRRA Trial Results Raise Questions About VTE Management

The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.

This week, host Craig Beavers sat down with Tara Lech, PharmD, CACP, director of anticoagulation services at Beth Israel Lahey Health, to discuss recent findings from the COBBRA trial, which compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.


Latest CME